XORTX Therapeutics (XRTX) Research & Development (2020 - 2026)
XORTX Therapeutics (XRTX) recorded Research & Development of $113,932 in the quarter ended Jun 30, 2026, down 39.0% from $186,751 a year earlier but up 244.1% from the prior quarter.
Powered by 
Analysis
XORTX Therapeutics (XRTX) Research & Development (2020 - 2026) Analysis & Trends
On a TTM basis, XORTX Therapeutics' Research & Development came in at $258,920 as of Jun 30, 2026, down 48.8% year-over-year; for the year ended Dec 31, 2025, it came in at $411,493, up 206.5% from the prior year.
- Annual Research & Development has a five-year compound annual growth rate of 14.7% (years ended Dec 2020 to Dec 2025).
- Across earlier years, Research & Development came in at $134,269 in the year ended Dec 31, 2024 (-92.5%), $1.79 million in the year ended Dec 31, 2023 (-73.5%), $6.76 million in the year ended Dec 31, 2022 (+897.9%) and $677,576 in the year ended Dec 31, 2021 (+227.2%).
- Quarterly Research & Development has ranged from $7,763 in the quarter ended Dec 31, 2024 to $2.44 million in the quarter ended Mar 31, 2022 over the past five years.
- On a year-over-year basis, Research & Development rose in four of the last eight quarters, with growth averaging 117.7%.
- Peak year-over-year performance for Research & Development in the last five years was growth of 606.7% in the quarter ended Dec 31, 2025, against a decline of 93.0% in the quarter ended Dec 31, 2023 at the low end.
- Per Business Quant, the preceding three quarters came in at $33,113 (quarter ended Mar 31, 2026), $54,864 (quarter ended Dec 31, 2025) and $57,011 (quarter ended Sep 30, 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | -4.05 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 993.80 Mn |
| 10 | XORTX Therapeutics | 1.62 Mn | -1.68 Mn | - | 113,932.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 113,932.00 |
| Mar 31, 2026 | 33,113.00 |
| Dec 31, 2025 | 54,864.00 |
| Sep 30, 2025 | 57,011.00 |
| Jun 30, 2025 | 186,751.00 |
| Mar 31, 2025 | 276,309.00 |
| Dec 31, 2024 | 7,763.00 |
| Sep 30, 2024 | 34,741.00 |
| Jun 30, 2024 | 67,683.00 |
| Mar 31, 2024 | 54,651.44 |
| Dec 31, 2023 | 98,524.72 |
| Sep 30, 2023 | 424,966.29 |
| Jun 30, 2023 | 497,229.48 |
| Mar 31, 2023 | 774,430.29 |
| Dec 31, 2022 | 1.40 Mn |
| Sep 30, 2022 | 1.13 Mn |
| Jun 30, 2022 | 1.14 Mn |
| Mar 31, 2022 | 2.44 Mn |
| Dec 31, 2021 | 430,948.00 |
| Sep 30, 2021 | 240,838.69 |
API Access
XORTX Therapeutics Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=XRTX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "XRTX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=XRTX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();